Myeloid-Derived Suppressor Cells
"Myeloid-Derived Suppressor Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous, immature population of myeloid cells that can suppress the activity of T-CELLS and NATURAL KILLER CELLS in the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNE RESPONSE. They play important roles in ONCOGENESIS; INFLAMMATION; and INFECTION.
| Descriptor ID |
D000072737
|
| MeSH Number(s) |
A11.627.817
|
| Concept/Terms |
Myeloid-Derived Suppressor Cells- Myeloid-Derived Suppressor Cells
- Cell, Myeloid-Derived Suppressor
- Cells, Myeloid-Derived Suppressor
- Myeloid Derived Suppressor Cells
- Myeloid-Derived Suppressor Cell
- Suppressor Cell, Myeloid-Derived
- Suppressor Cells, Myeloid-Derived
- MDSCs
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Derived Suppressor Cells".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Derived Suppressor Cells".
This graph shows the total number of publications written about "Myeloid-Derived Suppressor Cells" by people in this website by year, and whether "Myeloid-Derived Suppressor Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid-Derived Suppressor Cells" by people in Profiles.
-
NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma. Cancer Res Commun. 2025 Jun 01; 5(6):960-972.
-
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy. Cell Oncol (Dordr). 2025 Jun; 48(3):559-590.
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024; 13(1):2388304.
-
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 2024 01 09; 9(1).
-
Persistent immunosuppressive effects of dibutyl phthalate exposure in adult male mice. Sci Total Environ. 2023 Jun 20; 878:162741.
-
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023 02; 11(2).
-
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022 10; 8(10):839-854.
-
CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022 Feb; 41(7):971-982.
-
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2022 04; 28(4):203.e1-203.e7.
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).